The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Natural History of Insulin Sensitivity and Insulin Secretion in the Progression From Normal Glucose Tolerance to Impaired Fasting Glycemia and Impaired Glucose Tolerance: The Inter99 Study
Open accessAbstract
OBJECTIVE—The aim of this study was to describe the natural history of insulin secretion and insulin sensitivity in the development of isolated impaired fasting glycemia (i-IFG), isolated impaired glucose tolerance (i-IGT), and combined IFG/IGT. RESEARCH DESIGN AND METHODS—Baseline and 5-year follow-up data from the Inter99 study were used. Individuals with normal glucose tolerance (NGT) at baseline and i-IFG, i-IGT, combined IFG/IGT, or NGT at the 5-year follow-up were examined with an oral glucose tolerance test (n = 3,145). Insulin sensitivity index (ISI), homeostasis model assessment of insulin sensitivity (HOMA-IS), early-phase insulin release (EPIR), and insulin secretion relative to insulin action (disposition index) were estimated. RESULTS—Five years before the pre-diabetes diagnoses (i-IFG, i-IGT, and IFG/IGT), ISI, HOMA-IS, EPIR, and disposition index were lower than in individuals who maintained NGT. During the 5-year follow-up, individuals developing i-IFG experienced a significant decline only in HOMA-IS, whereas individuals developing i-IGT experienced significant declines in ISI, EPIR, and disposition index. Individuals with IFG/IGT exhibited pronounced declines in ISI, HOMA-IS, EPIR, and disposition index during the 5-year follow-up. CONCLUSIONS—A stationary reduced insulin secretion followed by a decline in primarily hepatic insulin sensitivity characterizes the transition from NGT to i-IFG. In contrast, low whole-body insulin sensitivity with a secondary lack of β-cell compensation is associated with the development of i-IGT. Thereby, i-IFG and i-IGT appear to result from different underlying mechanisms, which may have implications for the prevention and treatment of the diabetes that succeeds them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Randomized trials have shown beneficial effects of lifestyle intervention on diabetes risk in individuals with i-IGT and IFG/IGT (9,10), but whether lifestyle interventions have the same preventive effects in individuals with i-IFG is not known.”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Abdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Mooy, J. M., Grootenhuis, P. A., de Vries, H., Kostense, P. J., Popp-Snijders, C., Bouter, L. M., & Heine, R. J. (1996) · Diabetologia · doi:10.1007/bf00418345 · Cited by 344
Weyer, C., Bogardus, C., & Pratley, R. E. (1999) · Diabetes · doi:10.2337/diabetes.48.11.2197 · Cited by 292
β-cell failure as a complication of diabetes
Chang-Chen, K. J., Mullur, R., & Bernal-Mizrachi, E. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9101-5 · Cited by 225
Sicree, R. A., Zimmet, P. Z., Dunstan, D. W., Cameron, A. J., Welborn, T. A., & Shaw, J. E. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02362.x · Cited by 155
Cited by
Novel biomarkers for pre-diabetes identified by metabolomics
Wang‐Sattler, R., Yu, Z., Herder, C., Messias, A. C., Floegel, A., He, Y., Heim, K., Campillos, M., Holzapfel, C., Thorand, B., et al. (2012) · Molecular Systems Biology · doi:10.1038/msb.2012.43 · Cited by 701
Dang, K., Wang, X., Hu, J., Zhang, Y., Cheng, L., Qi, X., Liu, L., Ming, Z., Tao, X., & Li, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02115-9 · Cited by 599
Crusell, M. K. W., Hansen, T. H., Nielsen, T., Allin, K. H., Rühlemann, M. C., Damm, P., Vestergaard, H., Rørbye, C., Jørgensen, N. R., Christiansen, O. B., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0472-x · Cited by 480
Self-citationGast, K. B., Tjeerdema, N., Stijnen, T., Smit, J. W. A., & Dekkers, O. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052036 · Cited by 403
Che, B., Zhong, C., Zhang, R., Pu, L., Zhao, T., Zhang, Y., & Han, L. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01762-2 · Cited by 382
Færch, K., Borch-Johnsen, K., Holst, J. J., & Vaag, A. (2009) · Diabetologia · doi:10.1007/s00125-009-1443-3 · Cited by 252
Self-citationThe incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationPhenotypes of prediabetes and stratification of cardiometabolic risk
Stefan, N., Fritsche, A., Schick, F., & Häring, H.-U. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00082-6 · Cited by 208
Metadata
- Authors
- Færch, K., Vaag, A., Holst, J. J., Hansen, T., Jørgensen, T., & Borch-Johnsen, K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-03-01
- Volume
- 32
- Issue
- 3
- Pages
- 439-444
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1994576689
- Cited by
- 206
- References
- 13
- FWCI
- 9.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.